Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ziprasidone Mesylate

FDA-approved product (powder, intramuscular), marketed as Geodon, Ziprasidone Hydrochloride, Ziprasidone Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ziprasidone Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Cardiac arrhythmia
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Ventricular tachycardia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Indole derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ziprasidone Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ziprasidone Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Reducing Antipsychotic-Induced Weight Gain in Children With Metformin

    NCT01231074 · start 2010-02

    Registered record
    Registry ID
    NCT01231074
    Conditions
    Obesity; Weight Gain; Psychotropic Induced Weight Gain
    Interventions
    Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-02
    Completion
    2013-05
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Weight Gain; Psychotropic Induced Weight Gain
    InterventionMetformin
    PhasePhase 1
    Registry statusCompleted

  • Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

    NCT00910988 · start 2009-02

    Registered record
    Registry ID
    NCT00910988
    Conditions
    Hyperglycemia; Hyperlipidemia
    Interventions
    Olanzapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-02
    Completion
    2012-06
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperglycemia; Hyperlipidemia
    InterventionOlanzapine; Ziprasidone
    PhaseNot applicable
    Registry statusCompleted

  • Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation

    NCT01485692 · start 2009-02

    Registered record
    Registry ID
    NCT01485692
    Conditions
    Psychomotor Agitation
    Interventions
    haloperidol+promethazine; haloperidol + midazolam; olanzapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-02
    Completion
    2011-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychomotor Agitation
    Interventionhaloperidol+promethazine; haloperidol + midazolam; olanzapine; Ziprasidone
    PhaseNot applicable
    Registry statusCompleted

  • Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules

    NCT00821444 · start 2009-01

    Registered record
    Registry ID
    NCT00821444
    Conditions
    Healthy
    Interventions
    ziprasidone; B16 Fasted; B16 Fed
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-01
    Completion
    2009-03
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionziprasidone; B16 Fasted; B16 Fed
    PhasePhase 1
    Registry statusCompleted

  • A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder

    NCT00555997 · start 2008-03

    Registered record
    Registry ID
    NCT00555997
    Conditions
    Major Depressive Disorder
    Interventions
    Ziprasidone; Ziprasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-03
    Completion
    2010-06
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionZiprasidone; Ziprasidone; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Ziprasidone in the Psychosis Prodrome

    NCT00635700 · start 2008-03

    Registered record
    Registry ID
    NCT00635700
    Conditions
    Psychosis Prodrome
    Interventions
    ziprasidone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-03
    Completion
    2012-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis Prodrome
    Interventionziprasidone; placebo
    PhasePhase 2
    Registry statusCompleted

  • Juvenile Bipolar Disorder Outpatient Program

    NCT01000402 · start 2008-02

    Registered record
    Registry ID
    NCT01000402
    Conditions
    Bipolar Disorder; Attention Deficit Disorder With Hyperactivity
    Interventions
    Psychopharmacotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2014-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Attention Deficit Disorder With Hyperactivity
    InterventionPsychopharmacotherapy
    PhasePhase 4
    Registry statusUnknown

  • Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

    NCT00483548 · start 2007-10

    Registered record
    Registry ID
    NCT00483548
    Conditions
    Bipolar Disorder; Depression, Bipolar
    Interventions
    Ziprasidone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-10
    Completion
    2008-12
    Enrolment
    298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Depression, Bipolar
    InterventionZiprasidone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

    NCT00454883 · start 2007-04

    Registered record
    Registry ID
    NCT00454883
    Conditions
    Affective Psychosis, Bipolar; Mania; Manic-Depressive Psychosis
    Interventions
    ziprasidone
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-04
    Completion
    2007-12
    Enrolment
    379

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAffective Psychosis, Bipolar; Mania; Manic-Depressive Psychosis
    Interventionziprasidone
    PhaseNot recorded
    Registry statusCompleted

  • Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

    NCT00617058 · start 2007-03

    Registered record
    Registry ID
    NCT00617058
    Conditions
    Weight Gain
    Interventions
    metformin; healthy lifestyle intervention
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2007-03
    Completion
    2010-09
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWeight Gain
    Interventionmetformin; healthy lifestyle intervention
    PhasePhase 2
    Registry statusTerminated

  • Geodon in Weight Loss Study for Bipolar Disorders

    NCT00472641 · start 2007-01

    Registered record
    Registry ID
    NCT00472641
    Conditions
    Bipolar Disorder
    Interventions
    Ziprasidone/Geodon
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2009-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionZiprasidone/Geodon
    PhasePhase 4
    Registry statusCompleted

  • Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders

    NCT00676429 · start 2006-07

    Registered record
    Registry ID
    NCT00676429
    Conditions
    Conduct Disorder; Oppositional Defiant Disorder
    Interventions
    Ziprasidone Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-07
    Completion
    2008-06
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConduct Disorder; Oppositional Defiant Disorder
    InterventionZiprasidone Hydrochloride; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia

    NCT00257192 · start 2006-04

    Registered record
    Registry ID
    NCT00257192
    Conditions
    Schizophrenia
    Interventions
    placebo; Ziprasidone oral capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2006-04
    Completion
    2009-03
    Enrolment
    284

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionplacebo; Ziprasidone oral capsules
    PhasePhase 3
    Registry statusTerminated

  • Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)

    NCT00265330 · start 2006-03

    Registered record
    Registry ID
    NCT00265330
    Conditions
    Bipolar Disorder
    Interventions
    Ziprasidone oral capsules
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-01
    Enrolment
    169

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionZiprasidone oral capsules
    PhasePhase 3
    Registry statusCompleted

  • Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)

    NCT00229385 · start 2006-01

    Registered record
    Registry ID
    NCT00229385
    Conditions
    Schizophrenia; Obsessive Compulsive Disorder
    Interventions
    Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-01
    Completion
    2010-04
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Obsessive Compulsive Disorder
    InterventionZiprasidone
    PhaseNot applicable
    Registry statusCompleted